TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05564390

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mutation Carrier Screening
Description: Undergo rapid genetic testing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mutation Carrier Screening
Description: Undergo rapid genetic testing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT05932381

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical treatment
Description: the patients will receive routine medical treatment
Study: NCT06119945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1568
Description: One tablet of DWJ1568

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWC202215
Description: One tablet of DWC202215
Study: NCT06352801

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Compassion Intervention
Description: Children participants are expected to learn the concepts of self-compassion and strategies of applying self-compassion to their daily lives.
Study: NCT06281990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: 1. Patients who were planned to undergo sleeve gastrectomy surgery were informed about the perioperative period when they came to the outpatient clinic2-4weeks before surgery and were educated about the exercises to be performed before and after surgery. The content of this education included pain management, breathing exercises,foot rotation, and leg exercises. In addition, the education book prepared by the researchers was given to the patients to make the education and information permanent until the day of surgery.~2. When the patient was hospitalized, anxiety level with the Trait Anxiety scale and pain level with VAS were determined one day before surgery.~3. Postoperatively, the patient's pain level before analgesics every 4-6hours for 2days, the patient's anxiety level with the State Anxiety Scale one day after surgery, the development of complications in the postoperative period, vital signs were evaluated, and the duration of hospitalization was recorded.
Study: NCT04521153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab is administered at 200mg, q2w (2cycles) before radical surgery and 200mg, q3w (at least 6 cycles) after radical surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib Mesylate is administered at 250mg, qd (2 cycles) before radical surgery and 250mg, qd (at least 6 cycles) after radical surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE treatment
Description: TACE treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE treatment
Description: TACE treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical surgery
Description: Radical surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical surgery
Description: Radical surgery
Study: NCT05092724

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fetal blood transfusion
Description: transfusion of fetal blood
Study: NCT06244732

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative pain control
Description: Postoperative analgesia after OR-AAA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative pain control
Description: Postoperative analgesia after OR-AAA
Study: NCT06504095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention group (Flipped Teaching Method Group)
Description: Patient safety training will be provided to students using the flipped classroom teaching method, consisting of both out-of-class and in-class activities.~Out-of-Class Activity: For the Flipped Teaching method, a Learning Management System-Web-Based Distance Education System will be established. Lecture videos for each lesson will be uploaded to the system 7 days before the class day. Students will have the flexibility to watch the instructional videos as many times as they wish until the class day.~In-Class Activity: The researcher will come prepared for in-class activities such as question-answer sessions, discussions, brainstorming. No lecturing will be done by the researcher. The researcher will solely guide the students.
Study: NCT04700709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus Tab.
Description: Orally, once-daily in the morning - The first dose is administered within maximum 6mg/day according to the investigator's judgement, check the blood concentration of Sirolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3\~8ng/ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil Cap./Tab.
Description: Up to 1g BID(total 2g daily), PO
Study: NCT04934397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Infant Formula
Description: Powdered partially hydrolyzed whey (WPH) based infant formula with oligosaccharides
Study: NCT06040060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: The intervention was prepared by the research team (anesthesia resident) in the form of ketamine which had been diluted to a dosage of 10 mg/cc, taken according to the required dose based on actual body weight then diluted with 0.9% NaCl to 10 cc. Then the two solutions were given to researchers without knowing the contents of the drugs that had been prepared by the resident who assisted in this research.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: While the 0.9% NaCl solution was used as placebo was prepared in a 10 cc syringe
Study: NCT05830591

Intervention type: OTHER
Intervention: Characterization of the microbiome in oral and fecal samples
Description: The oral and fecal samples are collected during the periodical dental hygiene session at the odonto-stomatology unit and during day hospital for younger children admitted for the first clinical evaluation at Division of Child Neurology and Psychiatry. Procedures will follow standardized protocols.

Intervention type: OTHER
Intervention: Characterization of the microbiome in oral and fecal samples
Description: The oral and fecal samples are collected during the periodical dental hygiene session at the odonto-stomatology unit and during day hospital for younger children admitted for the first clinical evaluation at Division of Child Neurology and Psychiatry. Procedures will follow standardized protocols.

Intervention type: OTHER
Intervention: Characterization of the microbiome in oral and fecal samples
Description: The oral and fecal samples are collected during the periodical dental hygiene session at the odonto-stomatology unit and during day hospital for younger children admitted for the first clinical evaluation at Division of Child Neurology and Psychiatry. Procedures will follow standardized protocols.
Study: NCT06131177

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplement
Description: Protein supplement
Study: NCT04851834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTX-301
Description: Oral hypomethylating agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTX-301
Description: Oral hypomethylating agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTX-301
Description: Oral hypomethylating agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTX-301
Description: Oral hypomethylating agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTX-301
Description: Oral hypomethylating agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based Chemotherapy
Description: Standard of care for ovarian and bladder cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based Chemotherapy
Description: Standard of care for ovarian and bladder cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Standard of care for high-grade glioma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Standard of care for high-grade glioma
Study: NCT05705596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: 10% sucrose corresponding to a regular soft drink

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hesperetin
Description: increases sweetness of 7% sucrose solution to match sweetness of 10% sucrose solution
Study: NCT05564390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT06400342

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAVR-explant
Description: Surgical explantation of failed THV followed by surgical aortic valve replacement and any other cardiac surgeries deemed necessary.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Redo-TAVR
Description: Repeat transcatheter aortic valve implantation within a failed THV.
Study: NCT05193786

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Different level of PEEP
Description: Different level of PEEP (low versus high) was applied in noninvasive ventilation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Different level of PEEP
Description: Different level of PEEP (low versus high) was applied in noninvasive ventilation.
Study: NCT05741164

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06410612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: regional anesthesia and PAI
Description: this is the block portion of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PAI
Description: this is the no block portion of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PAI
Description: this is the no block portion of the study
Study: NCT06498154

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy combined with Neoadjuvant Radiotherapy
Description: Neoadjuvant radiotherapy: whole-breast irradiation ( 50 Gy in 25 fractions) plus a mandatory boost (14 Gy in seven fractions, which began on the day following completion of whole-breast irradiation) TCb (HP) \* : Triple negative patients will receive TCb regimens with or without immunotherapy and HER2 positive patients will receive TCb(HP) regimens.
Study: NCT05406440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189 4 mg and/or 12 mg tablet(s) will be administered orally QD for a total daily dose of 48 mg, 60 mg, 80 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189 4 mg and/or 12 mg tablet(s) will be administered orally QD for a total daily dose of 48 mg, 60 mg, 80 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189 4 mg and/or 12 mg tablet(s) will be administered orally QD for a total daily dose of 48 mg, 60 mg, 80 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MK-8189 dose-matching placebo tablets will be administered orally QD.
Study: NCT05248646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sibeprenlimab 400 mg
Description: Sibeprenlimab 400 mg s.c. q 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo s.c. q 4 weeks
Study: NCT06009627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalcelli、Exemestane、Gosserine
Description: Dalcelli: once a day, 125 mg each time, taken for 3 weeks, stopped for 1 week, 1 for 4 weeks~Period. It is recommended to take the medication at approximately the same time every day, delivered in warm water, on an empty stomach, at least before taking the medication~Fasting for 1 hour before and after.~Exemestane: 25mg, oral, once a day, continuous administration.~Gosserine: 3.6mg, subcutaneous injection, once every four weeks, continuous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection
Description: Docetaxel for injection: 75mg/m2, intravenous drip, approximately 30 minutes. Dose reduction and delayed administration are allowed every three weeks, with a maximum of three weeks of delayed administration allowed since the last administration time~Calculate, otherwise terminate treatment.~5. Epirubicin hydrochloride for injection: 75mg/m2, intravenous drip. Once every three weeks, allowing for dose reduction~And delayed administration, with a maximum allowable delay of 3 weeks, calculated from the last administration time. Otherwise~Stop treatment.~6. Cyclophosphamide for injection: 500mg/m2, intravenous drip. Once every three weeks, allowing for dose reduction and~Delayed administration, allowed up to 3 weeks, calculated from the last administration time, otherwise terminated treat
Study: NCT05368311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary recommendations including protein enriched bars
Description: Volunteers allocated in the experimental group will receive dietary recommendations and 2 protein enriched bars per day to be eaten 45 minutes before lunch and dinner.
Study: NCT05083949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC 12.5mg empagliflozin/850mg metformin
Description: empagliflozin/metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC 12.5mg empagliflozin/850mg metformin
Description: empagliflozin/metformin
Study: NCT05368311

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary recommendations without protein enriched bars
Description: Volunteers allocated in the experimental group will receive dietary recommendations.
Study: NCT05095571

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: EH301 (Nicotinamide Riboside/Pterostilbene)
Description: For this study EH301 is defined as Investigational Product(s) (IP). The ALS extension study is an open label study with active treatment of all patients thet have passed through the NO-ALS trial.
Study: NCT04565925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate
Description: Sildenafil 20mg TID for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate
Description: Sildenafil 20mg TID for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (Lactose) TID for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (Lactose) TID for 4 weeks
Study: NCT05083949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: empagliflozin 10mg (R1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: empagliflozin 10mg (R1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glifage®
Description: Glifage® 850mg (R2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glifage®
Description: Glifage® 850mg (R2)
Study: NCT05426967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Active rTMS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Active rTMS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham comparator to active rTMS
Study: NCT05911165

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No surgical coaching
Description: During the twelve-month study period, all participants will have access to an instructional video related to laparoscopic vaginal cuff suturing and the laparoscopic vaginal cuff trainer in order to practice laparoscopic suturing as desired. All participants will keep a log of voluntary practice time on the vaginal cuff trainer. These resources will constitute the control arm of the study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical coaching
Description: Surgical coaching sessions will include 30-60 minute meetings in which the coach-coachee pair reviews recorded laparoscopic suturing practice sessions to examine different aspects of surgical performance.
Study: NCT05480995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluorofuranylnorprogesterone PET / MRI
Description: Subjects will receive a PET/MRI with 18F-fluorofuranylnorprogesterone tracer
Study: NCT06414798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: ABBV-1088
Description: • Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: ABBV-1088
Description: • Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: ABBV-1088
Description: • Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: ABBV-1088
Description: • Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: ABBV-1088
Description: • Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: ABBV-1088
Description: • Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Placebo for ABBV-1088
Description: • Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Placebo for ABBV-1088
Description: • Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Placebo for ABBV-1088
Description: • Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Placebo for ABBV-1088
Description: • Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Placebo for ABBV-1088
Description: • Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Placebo for ABBV-1088
Description: • Oral Capsule
Study: NCT05257629

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Combination Therapy Arm (Varenicline and Nicotine E-Cigarettes Plus Counseling)
Description: Varenicline and nicotine e-cigarettes plus counseling

Intervention type: OTHER
Group type: OTHER
Intervention: Varenicline Plus Counseling
Description: Varenicline plus counseling
Study: NCT06218641

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CP - conventional protocol
Description: All patients will be treated with Biomax Nuvola aligners built based on the individual patient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of first aligner. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire.~The questionnaires will be completed at different stages of orthodontic treatment, as following:~* 24 hours after the delivery of the first aligner - start of orthodontic treatment;~* 3 days after the start of orthodontic treatment;~* 7 days after the start of orthodontic treatment;~* 24 hours after delivery of the third clear aligner;~* 3 days after delivery of the third clear aligner;~* 7 days after delivery of the third clear aligner.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DP - delayed protocol
Description: All patients will be treated with Biomax Nuvola aligners built based on the individual patient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of third aligner, approximately one month after the start of orthodontic treatment. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire.~The questionnaires will be completed at different stages of orthodontic treatment, as following:~* 24 hours after the delivery of the first aligner - start of orthodontic treatment;~* 3 days after the start of orthodontic treatment;~* 7 days after the start of orthodontic treatment;~* 24 hours after delivery of the third clear aligner;~* 3 days after delivery of the third clear aligner;~* 7 days after delivery of the third clear aligner.
Study: NCT06489340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2HPβCD
Description: 2HPβCD is a 7 D-glucopyranosyl derivation of cyclodextrin (CD) that entraps and passively removes intracellular cholesterol from the kidney. It is also believed to promote active cholesterol removal through up-regulation of cholesterol efflux transporters ABCA1 and ABCG1.